The comparative efficacy of Rivaroboxan and Enoxaparin for preventing the formation of thrombi after hip joint arthroplasty

Authors

  • Oleg Vyrva

DOI:

https://doi.org/10.15674/0030-59872009397-100

Keywords:

hip joint, arthroplasty, rivaroxaban, enoxaparin

Abstract

The article contains results of a randomized multinational double blind study (RECORG 1) of the efficacy and safety of Xarelto® (Rivaroxaban) for preventing deep vein thrombosis and pulmonary embolism in patients, who have survived an operation of hip joint replacement, versus Enoxaparin. The study involved 4,541 patients at the age of at least 18 years. Before the operation all the patients took the drugs once a day on an average during 35 days. A day after the last taking of the drugs the patients underwent bilateral venography. The content of renal enzymes in blood plasma was studied. It was proved that a single oral taking of Rivaroxaban could be used to prevent formation of thrombi after hip joint arthroplasty. If compared with Enoxaparin, Rivaroxaban was more effective for preventing development of venous thromboembolism, as it was evidenced by an absolute decrease of the risk of developing extensive venous thromboembolism by 2.6 % (relative risk decrease by 70 %) and thromboembolism of large veins by 1.7 % (relative risk decrease by 88 %). In patients, who underwent total hip joint arthroplasty, long-term (five weeks) prophylaxis of thrombus formation with help of oral taking of Rivaroxaban at a dose of 10 mg once a day was more effective than use of Enoxaparin at a dose of 40 mg once a day subcutaneously.

References

  1. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement / D. Bergqvist, G. Benoni, O. Bjorgell [et al.] // N. Engl. J. Med. — 1996. — Vol. 335. — P. 696–700.
  2. Eikelboom J.W. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials / J.W. Eikelboom, D.J. Quinlan, J.D. Douketis // Lancet. — 2001. — Vol. 358. — P. 9–15.
  3. Extended out-of-hospital low-molecularweight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review / R.D. Hull, G.F. Pineo, P.D. Stein [et al.] // Ann Intern Med. — 2001. — Vol. 135. — P. 858–869.
  4. Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with lowmolecular-weight heparin following elective hip arthroplasty: a systematic review / M. O’Donnell, L.A. Linkins, C. Kearon [et al.] // Arch. Intern. Med. — 2003. — Vol. 163. — P. 1362–1366.
  5. Davies L.M. Economic evaluation of enoxaparin as postdischarge prophylaxis for deep vein thrombosis (DVT) in elective hip surgery / L.M. Davies, G.A. Richardson, A.T. Cohen // Value Health. — 2000. — Vol. 3. — P. 397–406.
  6. Dahl O.E. Investment in prolonged thromboprophylaxis with dalteparin improves clinical outcomes after hip replacement / O.E. Dahl, A.M. Pleil // J. Thromb. Haemost. — 2003. — Vol. 1. — P. 896–906.
  7. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP. Conference on Antithrombotic and Thrombolytic Therapy / J. Ansell, J. Hirsh, L. Poller [et al.] // Chest. — 2004. — Vol. 126. — P. 204–233.
  8. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant / C.M. Samama, M. Vray, J. Barru [et al.] // Arch Intern Med. — 2002. — Vol. 162. — P. 2191–2196.
  9. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor / D. Kubitza, M. Becka, B. Voith [et al.] // Clin Pharmacol Ther. — 2005. — Vol. 78. — P. 412–421.
  10. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 — an oral, direct Factor Xa inhibitor — after multiple dosing in healthy male subjects / D. Kubitza, M. Becka, G. Wensing [et al.] // Eur. J. Clin. Pharmacol. — 2005. — Vol. 61. — P. 873–880.
  11. Dose-escalation study of rivaroxaban (BAY 59-7939) — an oral, direct Factor Xa inhibitor — for the prevention of venous thromboembolism in patients undergoing total hip replacement / B.I. Eriksson, L.C. Borris, O.E. Dahl [et al.] // Thromb. Res. — 2007. — Vol. 120. — P. 685–693.
  12. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement: a phase II dose-ranging study / A.G. Turpie, W.D. Fisher, K.A. Bauer [et al.] // J. Thromb. Haemost. — 2005. — Vol. 3. — P. 2479–2486.
  13. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement / B.I. Eriksson, L. Borris, O.E. Dahl [et al.] // J. Thromb. Haemost. — 2006. — Vol. 4. — P. 121–128.
  14. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement / B.I. Eriksson, L.C. Borris, O.E. Dahl [et al.] // Circulation. — 2006. — Vol. 114. — P. 2374–2381.
  15. Population pharmacokinetics and pharmacodynamics of rivaroxaban — an oral, direct Factor Xa inhibitor — in patients undergoing major orthopaedic surgery / W. Mueck, B.I. Eriksson, K.A. Bauer [et al.] // Clin. Pharmacokinet. — 2008. — Vol. 47. — P. 203–216.
  16. Rivaroxaban versus Enoxaparin for thromboprophylaxis after hip arthroplasty / B.I. Eriksson, L.C. Borris, R.J. Friedman [et al.] // N. Engl. J. Med. — 2008. — Vol. 358. — P. 2765–2775.
  17. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial / B.I. Eriksson, O.E. Dahl, N. Rosencher [et al.] // Lancet. — 2007. — Vol. 370. — P. 949–956.
  18. F F ondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized doubleblind studies / A.G. Turpie, K.A. Bauer, B.I. Eriksson, M.R. Lassen // Arch Intern. Med. — 2002. — Vol. 162. — P. 1833–1840.
  19. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study / B.I. Eriksson, G. Agnelli, A.T. Cohen [et al.] // J. Thromb. Haemost. — 2003. — Vol. 1. — P. 2490–2496.

Downloads

How to Cite

Vyrva, O. (2009). The comparative efficacy of Rivaroboxan and Enoxaparin for preventing the formation of thrombi after hip joint arthroplasty. ORTHOPAEDICS TRAUMATOLOGY and PROSTHETICS, (3), 97–100. https://doi.org/10.15674/0030-59872009397-100

Issue

No. 3 (2009)

Section

DIGESTS AND REVIEWS

License

Copyright (c) 2014 Oleg Vyrva

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The authors retain the right of authorship of their manuscript and pass the journal the right of the first publication of this article, which automatically become available from the date of publication under the terms of Creative Commons Attribution License, which allows others to freely distribute the published manuscript with mandatory linking to authors of the original research and the first publication of this one in this journal.

Authors have the right to enter into a separate supplemental agreement on the additional non-exclusive distribution of manuscript in the form in which it was published by the journal (i.e. to put work in electronic storage of an institution or publish as a part of the book) while maintaining the reference to the first publication of the manuscript in this journal.

The editorial policy of the journal allows authors and encourages manuscript accommodation online (i.e. in storage of an institution or on the personal websites) as before submission of the manuscript to the editorial office, and during its editorial processing because it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the published manuscript citation (see The Effect of Open Access).